SEATTLE, Feb. 8 /PRNewswire/ -- Trubion Pharmaceuticals, Inc. today announced the appointment of Steven Gillis, Ph.D., to the company’s board of directors. Dr. Gillis is a noted pioneer and experienced executive in the biopharmaceutical industry.
“We are pleased to welcome Steve to our board,” said Trubion chief executive officer Dr. Peter A. Thompson. “Not only does he bring extensive business acumen and experience to Trubion, he is a capable scientist and entrepreneur with a proven track record for transforming innovative technologies and products into significant value.”
Dr. Gillis joined ARCH in 2005 as a Venture Partner focused on the evaluation of new life science technologies and the development and growth of ARCH’s biotechnology portfolio companies. Prior to joining ARCH, Dr. Gillis founded Corixa Corporation (acquired by GlaxoSmithKline in 2005), where he served as the company’s chief executive officer since its inception and as chairman from 1999.
Dr. Gillis is also a founder of Immunex Corporation. From 1981 until his departure in 1994, he served as Immunex’s director of research and development, chief scientific officer, and chief executive officer of Immunex’s research and development subsidiary. Dr. Gillis was interim chief executive officer of Immunex following its majority purchase by American Cyanamid Company, and he remained a member of the board of directors until 1997. Immunex was acquired by Amgen Inc. in 2002.
An immunologist by training, Dr. Gillis has over 300 peer-reviewed publications in the areas of molecular and tumor immunology. He is credited as being a pioneer in the field of cytokines and cytokine receptors. Dr. Gillis received his B.A. from Williams College in 1975 and his Ph.D. from Dartmouth College in 1978.
“Trubion has excellent science, compelling product candidates, and a great team of professionals,” said Dr. Gillis. “I look forward to contributing to the company’s success.”
About Trubion
Trubion Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines to treat inflammatory disease and cancer. The company utilizes proprietary technology to develop drugs that are safer and more effective than currently available therapies. Trubion has multiple drug candidates in pre-clinical and clinical development. For additional information visit www.trubion.com.
CONTACT: Peter Thompson, MD, FACP of Trubion Pharmaceuticals, Inc., +1-206-838-0500.
Trubion Pharmaceuticals, Inc.
CONTACT: Peter Thompson, MD, FACP of Trubion Pharmaceuticals, Inc.,+1-206-838-0500
Web site: http://www.trubion.com//
